Disease Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

ID DOID:80375
Name gastroesophageal adenocarcinoma
Definition A gastroesophageal cancer that has_material_basis_in abnormally proliferating cells, derives_from epithelial cells, which originate in glandular tissue.
Source DiseaseOntology.org
Alt Ids
Path disease disease of cellular proliferation cancer organ system cancer gastrointestinal system cancer gastroesophageal cancer gastroesophageal adenocarcinoma


  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")


  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
ARID1A inact mut unspecified immune checkpoint inhibitor gastroesophageal adenocarcinoma not predictive detail...
FGFR2 over exp Bemarituzumab + Fluorouracil + Leucovorin + Oxaliplatin gastroesophageal adenocarcinoma predicted - sensitive detail...
RAD51C R237* Cisplatin + Fluorouracil + Trastuzumab gastroesophageal adenocarcinoma predicted - sensitive detail...
ATM R1882* Capecitabine + Oxaliplatin gastroesophageal adenocarcinoma predicted - sensitive detail...
ATM W1058* ATM S1993fs Fluorouracil + Leucovorin + Oxaliplatin gastroesophageal adenocarcinoma predicted - sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT02578368 Phase III Docetaxel + Fluorouracil + Leucovorin + Oxaliplatin Docetaxel + Fluorouracil + Leucovorin + Oxaliplatin + Trastuzumab Chemotherapy Alone vs. Chemotherapy + Surgical Resection in Patients With Limited-metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction (FLOT5) Active, not recruiting DEU 0
NCT02824042 Phase I Anetumab ravtansine + Itraconazole Anetumab ravtansine Thorough ECG (Electrocardiogram) and Drug Interaction Study With Anetumab Ravtansine and Itraconazole Completed USA | NLD | FRA | ESP | BEL | AUS 0
NCT02954536 Phase II Capecitabine + Cisplatin + Pembrolizumab + Trastuzumab Phase II Trial of Pembrolizumab With Trastuzumab and Chemotherapy in Advanced HER2 Positive Esophagogastric (EG) Cancer Completed USA 0
NCT03337087 Phase Ib/II Fluorouracil + Leucovorin + Liposomal irinotecan + Rucaparib Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer Active, not recruiting USA 0
NCT03697304 Phase II Ezabenlimab Miptenalimab Platform Trial Evaluating Safety and Efficacy of BI 754091 Anti- PD-1 Based Combination Therapies in PD-(L)1 naïve and PD- (L)1 Pretreated Patient Populations With Advanced/Metastatic Solid Tumours. Active, not recruiting USA | GBR | CAN 0
NCT03783936 Phase II Avelumab + Trastuzumab Avelumab + Fluorouracil + Leucovorin + Oxaliplatin + Trastuzumab Trial of mFOLFOX6 + Trastuzumab + Avelumab in Gastric and Esophageal Adenocarcinomas Completed USA 0
NCT03821233 Phase I ZW49 A Dose Finding Study of ZW49 in Patients With HER2-Positive Cancers Active, not recruiting USA | CAN | AUS 1
NCT03921021 Phase II OBP-301 + Pembrolizumab Phase 2 Study of Telomelysin (OBP-301) in Combination With Pembrolizumab in Esophagogastric Adenocarcinoma Completed USA 0
NCT03929666 Phase II Cisplatin + Gemcitabine Cisplatin + Fluorouracil + ZW25 Capecitabine + Oxaliplatin + ZW25 Fluorouracil + Leucovorin + Oxaliplatin + ZW25 Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin + ZW25 A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer Active, not recruiting USA | CAN 2
NCT03986606 Phase I PSB205 A Study of PSB205 in Subjects With Advanced Solid Tumors Unknown status USA 0
NCT04021108 Phase II Nivolumab Fluorouracil + Leucovorin + Nivolumab + Oxaliplatin Phase II Study of Short Course FOLFOX Chemotherapy With Either Nivolumab or Nivolumab + Radiation in the First Line Treatment of Metastatic or Unresectable Gastroesophageal Cancers (BMS Protocol CA209-76L) Active, not recruiting USA 0
NCT04029922 Phase I MT-5111 Study of MT-5111 in HER2-positive Solid Tumors (MT-5111) Terminated USA | NZL | AUS 0
NCT04060342 Phase Ib/II GB1275 GB1275 + Pembrolizumab GB1275 + Gemcitabine + Nab-paclitaxel GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma Terminated USA | GBR 0
NCT04150640 Phase II Fluorouracil + Liposomal irinotecan + Oxaliplatin Fluorouracil + Liposomal irinotecan + Oxaliplatin + Trastuzumab P2 5-FU, Oxaliplatin & Liposomal Irinotecan (Nal-IRI) in 1st Line Advanced Esophageal & Gastric Recruiting USA 0
NCT04164979 Phase II Cabozantinib + Pembrolizumab Ph II Study of Cabozantinib With Pembrolizumab in Metastatic Gastric and Gastroesophageal Adenocarcinoma Active, not recruiting USA 0
NCT04166721 Phase Ib/II Atezolizumab + DKN-01 WaKING: Wnt and checKpoint INhibition in Gastric Cancer Recruiting GBR 0
NCT04198766 Phase I INBRX-106 INBRX-106 + Pembrolizumab Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) Recruiting USA 0
NCT04511039 Phase I Talazoparib + Trifluridine-tipiracil hydrochloride Trifluridine/Tipiracil and Talazoparib for the Treatment of Patients With Locally Advanced or Metastatic Colorectal or Gastroesophageal Cancer Recruiting USA 0
NCT04522336 Phase I Docetaxel + Fluorouracil + Pembrolizumab Fluorouracil + Oxaliplatin + Pembrolizumab Pembrolizumab and Chemoradiotherapy for the Treatment of Unresectable Gastroesophageal Cancer Active, not recruiting USA 0
NCT04592653 Phase Ib/II ALKS 4230 ALKS 4230 + Pembrolizumab Less Frequent IV Dosing & Tumor Microenvironment (TME) Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy and in Combination With Pembrolizumab (ARTISTRY-3) (ARTISTRY-3) Recruiting USA | ESP 0
NCT04602117 Phase I Paclitaxel + Trastuzumab Duocarmazine Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer Withdrawn USA 0
NCT04662710 Phase III Capecitabine + Fluorouracil + Leucovorin + Oxaliplatin Capecitabine + Fluorouracil + Lenvatinib + Leucovorin + Oxaliplatin + Pembrolizumab Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-7902-015/E7080-G000-321/LEAP-015) (LEAP-015) Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS 15
NCT04798781 Phase II Pembrolizumab + Telatinib Safety and Efficacy of Telatinib in Combination With Keytruda in Subjects With Advanced Stomach and Gastroesophageal Junction Cancers or Hepatocellular Carcinoma Active, not recruiting USA 0
NCT04879368 Phase III Docetaxel Paclitaxel Trifluridine-tipiracil hydrochloride Nivolumab + Regorafenib Irinotecan RegoNivo vs Standard of Care Chemotherapy in AGOC (INTEGRATEIIb) Active, not recruiting USA | ITA | ESP | DEU | AUT | AUS 3
NCT04984733 Phase II Nivolumab + Temozolomide Temozolomide + Nivolumab in MGMT Methylated Oesophagogastric Cancer (ELEVATE) Recruiting GBR 0
NCT05001347 Phase II Uliledlimab A Clinical Study of TJ004309 With Atezolizumab (TECENTRIQ) in Patients With Ovarian Cancer and Selected Solid Tumors Completed USA 0
NCT05027139 Phase Ib/II Evorpacept + ZW25 A Study of Zanidatamab (ZW25) With Evorpacept (ALX148) in Patients With Advanced HER2-expressing Cancer Active, not recruiting USA 0
NCT05041153 Phase I Lenvatinib + Pembrolizumab Pembrolizumab and Lenvatinib for the Treatment of Advanced, Unresectable, or Metastatic Gastroesophageal Adenocarcinoma Recruiting USA 0
NCT05070247 Phase I TAK-500 Pembrolizumab + TAK-500 A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors Recruiting USA 0
NCT05143970 Phase I IPH5301 IPH5301 + Paclitaxel + Trastuzumab A Phase 1 First-In-Human Study of the Anti-CD73 IPH5301 Alone or in Combination With Chemotherapy and Trastuzumab in Patients With Advanced Solid Tumors (CHANCES) Recruiting FRA 0
NCT05152147 Phase III Capecitabine + Oxaliplatin + Trastuzumab Capecitabine + Oxaliplatin + ZW25 Cisplatin + Fluorouracil + Trastuzumab Cisplatin + Fluorouracil + ZW25 Cisplatin + Fluorouracil + Tislelizumab + ZW25 Capecitabine + Oxaliplatin + Tislelizumab + ZW25 A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers (HERIZON-GEA-01) Recruiting NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS 25
NCT05153304 Phase Ib/II Ipilimumab + Nivolumab A Phase I/II Study of Personalized Immunotherapy in Adults With Upper Gastrointestinal Tract Cancers Not yet recruiting USA 0
NCT05427487 Phase I IVX037 Study of Intratumoral IVX037 in Patients With Advanced or Metastatic Solid Tumours Recruiting AUS 0
NCT05523947 Phase Ib/II YH32367 Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor Recruiting AUS 1
NCT05620134 Phase Ib/II JK08 A Study of JK08, an IL-15 Antibody Fusion Protein Targeting CTLA-4, in Patients With Unresectable Locally Advanced or Metastatic Cancer Recruiting ESP | BEL 0
NCT05904496 Phase I BGB-30813 BGB-30813 + Tislelizumab A Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BGB-30813 Recruiting USA | ESP | AUS 0
NCT05977322 Phase I 177Lu-FF58 A Phase I Study of [177Lu]Lu-FF58 in Patients With Advanced Solid Tumors. Recruiting NLD | ESP 2
NCT06043427 Phase II Paclitaxel + Ramucirumab Paclitaxel + Ramucirumab + ZW25 Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Postive Advanced Gastroesophageal Adenocarcinoma Recruiting CAN 0
NCT06123468 Phase Ib/II Sacituzumab govitecan-hziy Study Evaluating Treatment of Sacituzumab-govitecan for Patients With Metastatic Esophagogastric Adenocarcinoma Recruiting DEU | AUT 0
NCT06154291 Phase Ib/II XON7 FIH XON7 in Advanced/Metastatic Solid Tumors (FIPO23) Recruiting FRA | BEL 0